Territory Worldwide. Term The term of the license will be []* PM-O Diligence PM-O will exert reasonable efforts to develop and introduce requirements the PT technology into the commercial market. Royalty PM-O will pay to PT []* royalties on net sales of licensed products (whether by PM-O or any licensee); in the event PM-O is required to license other third party technologies, this rate may be reduced by []* of royalties due to such third parties, but in no event will the rate payable by PM-O be reduced to less than (i) []* if the PT technology is the only adjuvant or delivery system required to commercialize a licensed product; (ii) []* if PM-O is required to license other adjuvant or delivery system technologies in order to commercialize a licensed product; (iii) []* if PT know-how only is used by PM-O to commercialize a licensed product. []* License Fee On execution of the License Agreement, PM-O will pay PT a non-refundable signing fee of []*. Milestone payments PM-O will pay to PT the following milestone payments: []* ---------------- * This portion of the Exhibit has been omitted pursuant to a Request for Confidential Treatment under Rule 406 of the Securities Act of 1933, as amended. The complete Exhibit, including the portions for which confidential treatment has been requested, has been filed separately with the Securities and Exchange Commission. []* []* General If the parties agree that PT should provide additional services (such as process development/manufacturing of clinical lots, toll manufacture, etc.), then the parties agree to negotiate additional payments to reflect this added input by PT. Governing Law Option and License Agreement to be under English law and jurisdiction. Please indicate Peptide Therapeutics agreement to the terms set out below in the space provided below. /s/ Xxxxx X. Xxxxxx /s/ Xxxx Xxxxxxxxxxx ------------------------------------ ------------------------------------ Xxxxx X. Xxxxxx, Ph.D. Xxxx Xxxxxxxxxxx XxxXxx Merieux Co. Merieux OraVax S.N.C. /s/ Xxxxxxx Xxxxxxx ------------------------------------ Xxxxxxx Xxxxxxx Director Peptide Therapeutics Limited ----------------- * This portion of the Exhibit has been omitted pursuant to a Request for Confidential Treatment under Rule 406 of the Securities Act of 1933, as amended. The complete Exhibit, including the portions for which confidential treatment has been requested, has been filed separately with the Securities and Exchange Commission. ATTACHMENT A Feasibility Study for H. pylori Vacc...
Territory Worldwide. Valid Claim a claim within (a) an issued/granted and unexpired patent; (b) a pending patent application which has not been pending for more than [**] from the date of the priority filing from which such pending application originates, and in each case which has not been withdrawn, cancelled, abandoned, disclaimed or revoked or held unpatentable, invalid or unenforceable by final decision of a court or other governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal.
Territory Worldwide. University The Chancellor, Masters and Scholars of the University of Cambridge Valid Claim a claim within (a) an issued/granted and unexpired patent; (b) a pending patent application which has not been pending for more than [**] from the date of the priority filing from which such pending application originates; (c) a pending patent application which has been pending for more than [**] from the date of the priority filing from which such pending application originates and where there is no Competing Product on sale in the territory where the claim is pending, and in each case ((a) to (c)) which has not been withdrawn, cancelled, abandoned, disclaimed or revoked or held unpatentable, invalid or unenforceable by final decision of a court or other governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed for appeal.
Territory Worldwide. University The Chancellor, Masters and Scholars of the University of Cambridge.
Territory Worldwide. Consumer Defined in Article 1 of the Agreement. User Data Defined in Article 1 of the Agreement. Mobile User Application Defined in Article 1 of the Agreement. Field of Use Consumer applications (including, for clarity, Internet, Web-based, mobile user and Mobile User Applications, databases and software products), based on interpretation and/or presentation of Wide Scale Health Related Information which is defined as one or more components of genetic information, clinical data and other information of individuals relating to human disease, health and/or wellness, in which the genetic information component (if such component is available) involves [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] Business Development Plan Prior to execution of a definitive license, LifeMap shall provide Mount Sinai with a detailed business development plan. The Parties shall discuss in good faith any of Mount Sinai’s requests for additional details or clarifications to such business development plan. Due Diligence LifeMap shall use reasonable commercial efforts to develop and commercialize Licensed Products. LifeMap shall be required to demonstrate suitable investment in the development of Licensed Products. The Parties shall negotiate in good faith defined diligence milestones and timelines to be included in the definitive license agreement to ensure such Licensed Products are being diligently developed. Diligence Milestone Due Date Documentation of at least [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] in funding [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] committed by LifeMap to fund development of Licensed Products (the investment made into LifeMap prior to the due date will be counted toward the funding sum above) [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] months after execution of definitive license agreement Prototype complete [*Certain information has been omitted under a request for confidential treatment, and the omitted information has been filed with the Commission] months after execution of definitive license agreement Beta launch [*Certain information has been o...
Territory Worldwide. The Celaden Project Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever NUS Ref: LL2013-14
Territory Worldwide. Sirtuin Modulator Field All indications, including but not limited to metabolic diseases, oncology, CNS indications (including Huntington’s Disease and other neurodegenerative diseases) and HIV. Sirtuin Modulator Intellectual Property All IP owned and licensable or otherwise controlled by Elixir related to the Sirtuin Modulators or Sirtuin Modulator Products, including all IP licensed to Elixir under the Siena Agreement. Development Efforts Elixir will use commercially reasonable efforts to research and develop one or more Sirtuin Modulators for so long as Novartis continues to have any outstanding rights as set forth below. Rights of Negotiation Preconditions to Novartis’s rights below: (A) either (I) BMS has not granted a Waiver; or (II) BMS has granted a Waiver but Elixir and BMS have not amended the definition of “Competitive Compound” under the BMS License Agreement such that it is limited to other Ghrelin Agonists; and (B) None of the BMS Ghrelin Agonists or Non-BMS Ghrelin Agonists has previously reached Proof of Concept. Subject to Preconditions (A) and (B) above, Novartis will have a right of exclusive negotiation to obtain license(s) (and sublicense(s)) from Elixir under the Sirtuin Modulator Intellectual Property to research, develop, manufacture and commercialize certain Sirtuin Modulators and certain Sirtuin Modulator Products in the Sirtuin Modulator Field throughout the Territory, as set forth below. Elixir will provide notice to Novartis within * of the first of the Available Sirtuin Modulators to reach the end of preclinical development. Such notice shall be accompanied by a report setting forth all information in Elixir’s possession or control * Confidential Treatment Requested 6 RIGHTS AGREEMENT which is reasonably requested and required by Novartis to determine whether it wishes its rights hereunder to apply to such Available Sirtuin Modulator. Novartis will have the right, exercisable by written notice within * of Elixir’s notice, to reject such Available Sirtuin Modulator, in which case Novartis’ rights hereunder shall not apply to such rejected Available Sirtuin Modulator (and, for clarity, such rights will continue to apply to the next Available Sirtuin Modulator to reach Proof of Concept, excluding such rejected Available Sirtuin Modulator). For the avoidance of doubt, such right of rejection shall apply only with respect to the first Available Sirtuin Modulator to reach the end of preclinical development, and Novartis shall only h...
Territory Worldwide. TVOD transactional video on demand being exhibition by Electronic Transmission for which a fee is made for viewing and re-viewing (on a temporary basis) at a time chosen by the viewer for their personal and/or private viewing purposes only Viewing Device television receiver, set top box, personal computer, mobile device, tablet, games console, portable and/or other analogous devices or terminals capable of receiving, downloading, storing, onward transmitting and/or playing back Electronic Transmission. Writer’s Share 22.5% of the Artist’s Profit Participation Pool. SCHEDULE 2 (to the NTAH Minimum Terms Agreement) PROHIBITED CLASSES OF SPONSOR For the avoidance of doubt, any NT Global Sponsor(s) shall not have as its primary source of business the following activities: Gambling The sale of tobacco Mining of oil, gas and other fossil fuels Arms manufacturers Any sponsorship deals or arrangements with any other sponsor or partner, including the NT Global Sponsor(s), shall be in line with this Schedule and the NT’s Donation and Sponsorship Acceptance Policy, a copy of which is available at the following link (xxxxx://xxx.xxxxxxxxxxxxxxx.xxx.xx/your-visit/policies/donation-and-sponsorship-acceptance-statement) and replicated here, for reference: Donation and Sponsorship acceptance statement The National Theatre is a Registered Charity (No. 224223) and relies on voluntary contributions from its audience and other funders. Donations and sponsorship help every element of the National Theatre’s work both on stage and off. From the creative teams that produce our most awe-inspiring shows to the creation of our remarkable Learning programmes and development of new work at the NT Studio, voluntary contributions enable us to continue working to the highest possible standards. We are committed to fundraising best practice and abide by the Fundraising Regulator’s key principles and behaviours of a fundraising organisation: to be legal, open, honest and respectful. We undertake to comply with relevant law and regulations, including the Proceeds of Crime Act, Data Protection, Tax and Gift Aid legislation, and Charity Commission guidance, as well as the National Theatre’s corporate policies, such as Anti-Bribery. The Development Department monitors potential donations and corporate partnerships for compliance and risk. Final decisions may be escalated to the Board of Trustees. It is our Board’s legal obligation to act in the best long-term interest of the National Theatre a...
Territory Worldwide. License Fee: Lightlake shall pay to Aegis a nonrefundable and noncreditable license fee of *** REDACTED ***on the effective date of the license agreement. *** REDACTED ONE PARAGRAPH AND FOUR CLAUSES *** Confidential Treatment Requested by Lightlake Therapeutics Inc. IRS Employer Identification No. 40-0000000 Confidential treatment requested with respect to certain portions hereof denoted with “*** REDACTED ***”
Territory Worldwide. Fig Keys Developer will provide Fig with 100 Fig Keys (as defined in the Terms and Conditions) at no charge, at least ten (10) days prior to the Release Date, which Fig may use, offer, sell or otherwise dispose of as provided in this Agreement. Developer Bank Information Bank Name: Umpqua Bank Routing Number: 000000000 Accounting Number: 4867148886 Fig’s Address for Notices 000 0xx Xxxxxx, Xxxxx 00 Xxx Xxxx, Xxx Xxxx 00000 Attn: Fig Legal E-mail: xxxxxx.xxxxx@xxxxxxxx.xx Developer’s Address for Notices 000 XX 0xx Xxx #000, Xxxxxxxx XX, 00000 Attn: Xxxxx Warning E-mail: xxxxx@xxxxxxxxxxxxx.xxx
